Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
118.38
-1.42 (-1.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
29
30
Next >
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2025
From
Incyte
Via
Business Wire
NASDAQ:INCY, an undervalued stock with good fundamentals.
↗
December 26, 2024
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
↗
December 19, 2024
Via
Benzinga
Incyte to Present at Upcoming Investor Conference
December 17, 2024
From
Incyte
Via
Business Wire
Incyte Corporation (INCY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
December 17, 2024
Via
ACCESSWIRE
Cracking The Code: Understanding Analyst Reviews For Incyte
↗
November 14, 2024
Via
Benzinga
Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY
December 16, 2024
Via
ACCESSWIRE
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY
December 13, 2024
Via
ACCESSWIRE
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
↗
December 13, 2024
Via
The Motley Fool
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
December 10, 2024
From
Incyte
Via
Business Wire
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
December 07, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From
Incyte
Via
Business Wire
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
November 26, 2024
From
Incyte
Via
Business Wire
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
November 25, 2024
From
Incyte
Via
Business Wire
Target, Alibaba And Temu Parent PDD Are Among Top 10 Large-Cap Losers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio?
↗
November 24, 2024
Large-cap stocks had a rough week, including Target, PDD Holdings, ZTO Express, Tenet Healthcare, Ulta Beauty, Intuit, Nokia, Alibaba, Santander, and Incyte.
Via
Benzinga
Stock Market Rallies After Key Test; Nvidia, Target, Google, Bitcoin In Focus: Weekly Review
↗
November 22, 2024
Many leaders flashed buy signals. Bitcoin raced toward $100,000.
Via
Investor's Business Daily
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
↗
November 20, 2024
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
November 19, 2024
Via
Benzinga
Nasdaq Reverses Losses Amid Nvidia Fanfare
↗
November 19, 2024
Stocks are attempting to walk back this morning's losses tied to escalating tensions between Russia and Ukraine.
Via
Talk Markets
Gold Moves Higher; Medtronic Posts Upbeat Results
↗
November 19, 2024
Via
Benzinga
Stocks Move Higher, Walmart Hits Record High, Natural Gas Reaches 5-Month Peak: What's Driving Markets Tuesday?
↗
November 19, 2024
Wall Street managed to recover from a red start caused by heightened geopolitical tensions stemming from the ongoing Russia-Ukraine conflict.
Via
Benzinga
Topics
Energy
What's Going On With Incyte Shares Tuesday?
↗
November 19, 2024
Incyte stock is trading lower on Tuesday after the company announced that data from its Phase 2 study does not support further development.
Via
Benzinga
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
November 19, 2024
Via
Benzinga
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
↗
November 19, 2024
Incyte pauses MRGPRX2 study enrollment due to toxicology concerns, with analysts calling the update disappointing amid pipeline reevaluations.
Via
Benzinga
Nasdaq Gains 100 Points; Lowe's Earnings Beat Views
↗
November 19, 2024
Via
Benzinga
Topics
Earnings
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
↗
November 19, 2024
The company is discontinuing development of one drug and pausing enrollment in the study of another.
Via
Investor's Business Daily
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
↗
November 19, 2024
Via
Benzinga
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
November 18, 2024
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
November 14, 2024
From
Incyte
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 13, 2024
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
29
30
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
